 Connection
Siddhartha Mitra to Rhabdoid Tumor
This is a "connection" page, showing publications Siddhartha Mitra has written about Rhabdoid Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.505 |
|
|
|
-
Pauck D, Picard D, Maue M, Taban K, Marquardt V, Blümel L, Bartl J, Qin N, Kubon N, Schöndorf D, Meyer FD, Theruvath J, Mitra S, Hasselblatt M, Frühwald MC, Reifenberger G, Remke M. An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT). Pharmacol Res. 2025 Mar; 213:107660.
Score: 0.200
-
Alimova I, Wang D, Danis E, Pierce A, Donson A, Serkova N, Madhavan K, Lakshmanachetty S, Balakrishnan I, Foreman NK, Mitra S, Venkataraman S, Vibhakar R. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. Int J Oncol. 2022 Mar; 60(3).
Score: 0.162
-
Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A, Majzner RG, Xu P, Mueller S, Yecies DW, Finetti MA, Williamson D, Johann PD, Kool M, Pfister S, Hasselblatt M, Frühwald MC, Delattre O, Surdez D, Bourdeaut F, Puget S, Zaidi S, Mitra SS, Cheshier S, Sorensen PH, Monje M, Mackall CL. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nat Med. 2020 05; 26(5):712-719.
Score: 0.143
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|